IDO1 and ovarian cancer: Altogether, the impact of tumoral IDO1 expression in ovarian cancer was not only confined to the kynurenine pathway, but also affected nicotinamide, purine and pyrimidine metabolic pathways, and the magnitude of change was influenced by the tumor burden.